Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Open in Screener

AURA

Aura Biosciences Inc

Oct 23 • 10:19AM ET

11.02

Dollar change -0.37
Percentage change -3.25	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP EDIT FATE ARVN GRTS MORF ITCI KURA RVNC MEIP

| Held by: IWM VTI VXF IWN VTWO IWC ITOT DFAS AVSC SBIO

Index	RUT	P/E	-	EPS (ttm)	-1.79	Insider Own	13.89%	Shs Outstand	49.35M	Perf Week	7.51%
Market Cap	546.70M	Forward P/E	-	EPS next Y	-2.03	Insider Trans	-0.83%	Shs Float	42.71M	Perf Month	21.10%
Income	-80.69M	PEG	-	EPS next Q	-0.44	Inst Own	72.68%	Short Float	2.69%	Perf Quarter	7.30%
Sales	0.00M	P/S	-	EPS this Y	10.72%	Inst Trans	1.29%	Short Ratio	6.37	Perf Half Y	55.21%
Book/sh	3.86	P/B	2.85	EPS next Y	-18.01%	ROA	-39.26%	Short Interest	1.15M	Perf Year	29.65%
Cash/sh	3.78	P/C	2.92	EPS next 5Y	-	ROE	-45.09%	52W Range	5.99 - 12.38	Perf YTD	24.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.85%	ROI	-38.84%	52W High	-10.97%	Beta	0.39
Dividend TTM	-	Quick Ratio	18.54	Sales past 5Y	0.00%	Gross Margin	-	52W Low	83.97%	ATR (14)	0.62
Dividend Ex-Date	-	Current Ratio	18.54	EPS Y/Y TTM	10.80%	Oper. Margin	0.00%	RSI (14)	66.64	Volatility	6.18% 5.63%
Employees	89	Debt/Eq	0.10	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	22.43
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	15.10%	Payout	-	Rel Volume	0.37	Prev Close	11.39
Sales Surprise	-	EPS Surprise	8.91%	Sales Q/Q	-	Earnings	Aug 08 BMO	Avg Volume	180.72K	Price	11.02
SMA20	16.02%	SMA50	24.36%	SMA200	34.88%	Trades		Volume	11,279	Change	-3.25%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-24	Initiated	H.C. Wainwright	Buy	$21
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Apr-17-23	Resumed	BTIG Research	Buy	$38
Jul-19-22	Initiated	JMP Securities	Mkt Outperform	$26

Oct-17-24 04:05PM	Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial (GlobeNewswire) +14.09%
Sep-12-24 06:30AM	Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma (GlobeNewswire) +7.94%
Sep-03-24 04:05PM	Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024 (GlobeNewswire) -7.04%
Aug-28-24 04:05PM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-24 04:05PM	Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting (GlobeNewswire)
07:00AM	Loading…
Aug-08-24 07:00AM	Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jun-06-24 09:55AM	Wall Street Analysts See a 162.63% Upside in Aura Biosciences (AURA): Can the Stock Really Move This High? (Zacks)
May-30-24 04:05PM	Aura Biosciences to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-24 08:00AM	Aura Biosciences to Host Virtual KOL Event Pioneering a New Standard of Care In Ocular Oncology on May 29, 2024 (GlobeNewswire)
May-10-24 02:58PM	Aura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial Overview (GuruFocus.com)
May-09-24 01:55PM	AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-08-24 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-27-24 01:53PM	AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
05:20PM	Loading…
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Feb-26-24 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Dec-11-23 09:55AM	Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a Bet (Zacks) -8.46%
Dec-07-23 08:00AM	Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma (Business Wire)
Nov-23-23 09:55AM	Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to Trade (Zacks)
Nov-09-23 04:05PM	Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) +9.54%
Nov-08-23 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Nov-06-23 10:02PM	Aura Biosciences Announces Pricing of Public Offering of Common Stock (Business Wire) -8.18% -32.55%
04:08PM	Aura Biosciences Announces Proposed Public Offering of Common Stock (Business Wire)
03:00PM	Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma (Business Wire)
Oct-31-23 04:05PM	Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023 (Business Wire) +9.24% +9.93%
Oct-02-23 04:05PM	Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments (Business Wire) -7.47%
Aug-09-23 07:00AM	Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) -6.62%
Jul-31-23 06:07AM	Owning 38% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA), (Simply Wall St.)
May-24-23 04:05PM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire) -5.29%
07:00AM	Loading…
May-12-23 07:00AM	Aura Biosciences to Participate in the JMP Securities Life Sciences Conference (Business Wire)
May-11-23 04:10PM	Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
May-03-23 07:52AM	Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year (Simply Wall St.)
Mar-15-23 04:10PM	Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
11:11AM	Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth (Simply Wall St.)
Feb-16-23 10:43AM	Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate (Benzinga) -7.17%
07:00AM	Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration (Business Wire)
Feb-10-23 06:03AM	Why Shares of Aura Biosciences Jumped This Week (Motley Fool)
Feb-09-23 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Dec-24-22 09:27AM	Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 11% drop adds to a year losses (Simply Wall St.)
Dec-16-22 09:54AM	12 Stocks Insiders are Buying Now (Insider Monkey)
Nov-30-22 08:50PM	Aura Biosciences Announces Pricing of Public Offering of Common Stock (Business Wire) -6.02%
04:01PM	Aura Biosciences Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-24-22 06:34AM	Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year (Simply Wall St.)
Nov-10-22 07:00AM	Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
06:45AM	Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma (Business Wire)
Nov-03-22 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Oct-06-22 10:12AM	Here's Why We're Not Too Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Situation (Simply Wall St.)
Oct-04-22 07:05AM	Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedicals Proprietary Suprachoroidal Space Platform (GlobeNewswire)
Oct-03-22 01:37PM	Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug (Benzinga) -19.48%
07:00AM	Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022 (Business Wire)
Sep-28-22 07:00AM	Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer (Business Wire) +19.23%
Sep-27-22 07:00AM	Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 (Business Wire) +5.12%
Sep-07-22 07:00AM	Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress (Business Wire)
Sep-01-22 07:00AM	Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress (Business Wire)
Aug-11-22 04:15PM	Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) -8.60% +8.89%
Aug-02-22 07:00AM	Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference (Business Wire)
Jul-19-22 03:04PM	JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer" (Benzinga) +7.67%
Jul-17-22 08:36AM	Could The Aura Biosciences, Inc. (NASDAQ:AURA) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jun-30-22 08:51AM	Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate (MarketWatch) +12.73%
07:00AM	Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer (Business Wire)
Jun-23-22 08:44AM	Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer (Benzinga) -6.00%
Jun-22-22 04:30PM	Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma (Business Wire)
Jun-17-22 07:00AM	Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting (Business Wire) +6.92%
06:40AM	Bullish Aura Biosciences, Inc. (NASDAQ:AURA) investors are yet to receive a pay off on their US$716k bet (Simply Wall St.)
May-26-22 05:26PM	Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting (Business Wire)
May-25-22 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
May-12-22 04:15PM	Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) +5.82%
May-03-22 04:05PM	Aura Biosciences Presents Preclinical Data Highlighting AU-011s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting (Business Wire)
07:00AM	Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference (Business Wire)
Apr-29-22 07:53AM	We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth (Simply Wall St.) +6.33%
Mar-23-22 04:15PM	Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
Mar-21-22 07:00AM	Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma) (Business Wire)
Mar-15-22 07:00AM	Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22 (Business Wire) +8.57%
Mar-08-22 04:30PM	Aura Biosciences to Present Preclinical Data Highlighting AU011s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting (Business Wire) +5.81%
Feb-28-22 07:00AM	Aura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care Conference (Business Wire)
Feb-14-22 05:00PM	Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium (Business Wire) +13.09%
Feb-09-22 08:00AM	Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference (Business Wire)
Feb-03-22 01:38PM	Medicxi Ventures Management (Jersey) Ltd Buys Aura Biosciences Inc (GuruFocus.com)
Jan-29-22 07:52AM	What Percentage Of Aura Biosciences, Inc. (NASDAQ:AURA) Shares Do Insiders Own? (Simply Wall St.)
Nov-24-21 04:05PM	Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) +11.36% +13.16%
Nov-23-21 04:05PM	Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference (Business Wire) -9.43%
Nov-15-21 11:00AM	Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting (Business Wire) +18.35%
Oct-28-21 09:39PM	Aura Biosciences Announces Pricing of Initial Public Offering (Business Wire)

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Feder Julie B	Chief Financial Officer	Oct 18 '24	Option Exercise	3.44	25,131	86,532	159,407	Oct 21 06:23 PM
Feder Julie B	Chief Financial Officer	Oct 18 '24	Sale	12.03	25,131	302,361	134,276	Oct 21 06:23 PM
de los Pinos Elisabet	See Remarks	Oct 18 '24	Option Exercise	2.74	24,992	68,478	354,839	Oct 18 08:08 PM
de los Pinos Elisabet	See Remarks	Oct 18 '24	Sale	12.04	24,992	300,839	329,847	Oct 18 08:08 PM
JULIE FEDER	Officer	Oct 18 '24	Proposed Sale	10.29	25,131	258,598		Oct 18 04:21 PM
ELISABET DE LOS PINOS	Director	Oct 18 '24	Proposed Sale	10.29	24,992	257,168		Oct 18 04:21 PM
Plavsic Mark	Chief Technology Officer	Oct 16 '24	Sale	9.85	7,383	72,723	121,132	Oct 16 09:25 PM
Plavsic Mark	Officer	Oct 16 '24	Proposed Sale	9.85	7,383	72,723		Oct 16 09:22 PM
de los Pinos Elisabet	See Remarks	Sep 27 '24	Option Exercise	5.76	5,474	31,530	329,847	Oct 01 05:08 PM
de los Pinos Elisabet	See Remarks	Jan 23 '24	Sale	7.64	15,853	121,141	161,438	Jan 24 04:20 PM
Feder Julie B	Chief Financial Officer	Jan 23 '24	Sale	7.64	6,609	50,521	62,991	Jan 24 04:18 PM
Johnson David Michael	Director	Nov 07 '23	Buy	7.17	94,000	673,980	65,000	Nov 09 05:02 PM
Johnson David Michael	Director	Nov 07 '23	Buy	7.17	76,000	544,920	126,066	Nov 09 05:02 PM
Johnson David Michael	Director	Nov 08 '23	Buy	7.30	20,000	146,000	75,000	Nov 09 05:02 PM
Johnson David Michael	Director	Nov 08 '23	Buy	7.30	9,601	70,087	135,667	Nov 09 05:02 PM
Matrix Capital Management Comp	10% Owner	Nov 09 '23	Buy	9.00	1,560,000	14,040,000	6,922,870	Nov 09 04:35 PM
de los Pinos Elisabet	See Remarks	Nov 06 '23	Option Exercise	2.74	3,800	10,412	184,740	Nov 07 06:19 PM
de los Pinos Elisabet	See Remarks	Nov 06 '23	Sale	12.03	7,449	89,611	177,291	Nov 07 06:19 PM
Feder Julie B	Chief Financial Officer	Nov 06 '23	Option Exercise	2.74	3,900	10,686	73,500	Nov 07 06:09 PM
Feder Julie B	Chief Financial Officer	Nov 06 '23	Sale	12.07	3,900	47,054	69,600	Nov 07 06:09 PM
Feder Julie B	Chief Financial Officer	Oct 30 '23	Sale	6.82	3,385	23,091	69,600	Nov 01 06:24 PM
de los Pinos Elisabet	See Remarks	Oct 30 '23	Sale	6.83	9,586	65,478	180,940	Nov 01 06:21 PM

Open in Screener

FATE

Fate Therapeutics Inc

Oct 23 • 10:19AM ET

3.11

Dollar change -0.08
Percentage change -2.56	%

Healthcare • Biotechnology • USA • NASD

FATE Fate Therapeutics Inc daily Stock Chart

Peers: GILD CRSP BLUE SRPT EDIT NTLA CLLS SGMO CARA VTVT

| Held by: VTI IWM XBI VXF IWN DFAT KOMP VTWO SCHA VHT

Index	RUT	P/E	-	EPS (ttm)	-1.71	Insider Own	16.69%	Shs Outstand	98.63M	Perf Week	-3.17%
Market Cap	353.97M	Forward P/E	-	EPS next Y	-1.65	Insider Trans	-0.00%	Shs Float	94.87M	Perf Month	-9.90%
Income	-175.72M	PEG	-	EPS next Q	-0.42	Inst Own	93.19%	Short Float	14.94%	Perf Quarter	-42.44%
Sales	12.32M	P/S	28.73	EPS this Y	-0.05%	Inst Trans	-0.65%	Short Ratio	10.21	Perf Half Y	-27.71%
Book/sh	3.49	P/B	0.89	EPS next Y	-0.81%	ROA	-31.56%	Short Interest	14.18M	Perf Year	72.68%
Cash/sh	2.68	P/C	1.16	EPS next 5Y	-	ROE	-42.10%	52W Range	1.63 - 8.83	Perf YTD	-16.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-6.65%	ROI	-35.80%	52W High	-64.80%	Beta	1.84
Dividend TTM	-	Quick Ratio	9.18	Sales past 5Y	87.14%	Gross Margin	-55.61%	52W Low	90.69%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	9.18	EPS Y/Y TTM	21.30%	Oper. Margin	-1587.28%	RSI (14)	41.63	Volatility	5.79% 5.94%
Employees	181	Debt/Eq	0.25	Sales Y/Y TTM	-89.67%	Profit Margin	-1426.67%	Recom	2.65	Target Price	6.62
Option/Short	Yes / Yes	LT Debt/Eq	0.24	EPS Q/Q	38.99%	Payout	-	Rel Volume	0.36	Prev Close	3.19
Sales Surprise	410.52%	EPS Surprise	28.80%	Sales Q/Q	625.83%	Earnings	Aug 13 AMC	Avg Volume	1.39M	Price	3.11
SMA20	-2.62%	SMA50	-10.67%	SMA200	-33.63%	Trades		Volume	84,071	Change	-2.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-24	Upgrade	Piper Sandler	Neutral → Overweight	$4 → $6
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$6
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral	$115 → $7
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral	$42 → $7
Jan-06-23	Downgrade	Truist	Buy → Hold	$46 → $7
Jan-06-23	Downgrade	Stifel	Buy → Hold	$107 → $5.30
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral	$71 → $12
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$72 → $4
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$20 → $7
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell	$10
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight	$98 → $45
Oct-10-22	Initiated	Canaccord Genuity	Buy	$42
Aug-18-22	Resumed	Wells Fargo	Overweight	$90
Jul-28-22	Initiated	Needham	Hold
Jul-11-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$50 → $47
Jun-03-22	Initiated	Robert W. Baird	Neutral	$28
Feb-11-22	Resumed	BMO Capital Markets	Market Perform	$50

Show Previous Ratings

Oct-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-24 04:01PM	Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference (GlobeNewswire) +7.49%
11:30AM	Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? (Zacks)
Aug-16-24 12:00PM	All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy (Zacks)
Aug-13-24 05:25PM	Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:25PM	Loading…
04:25PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
Aug-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.12% -9.50%
Jul-31-24 08:00AM	Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors (GlobeNewswire)
Jul-21-24 05:37AM	Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? (Motley Fool)
Jul-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 04:01PM	Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-24 10:48AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 02:50PM	Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ... (GuruFocus.com)
10:36AM	Loading…
10:36AM	Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating (MT Newswires)
08:22AM	Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating (MT Newswires)
May-09-24 08:58PM	FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.41%
05:25PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:21PM	Fate Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates (GlobeNewswire)
08:30AM	Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program (GlobeNewswire)
May-06-24 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
May-03-24 04:30PM	Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting (GlobeNewswire)
Apr-22-24 04:30PM	Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting (GlobeNewswire) -5.02%
Apr-06-24 02:17AM	Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress (Zacks)
Apr-04-24 11:30PM	NOTICE TO LONG-TERM SHAREHOLDERS OF FATE THERAPEUTICS, INC. (FATE): GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON YOUR BEHALF (Newsfile)
Apr-03-24 08:00AM	Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-24 11:30AM	Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound? (Zacks) +7.00%
08:44AM	Loading…
Mar-19-24 08:44AM	Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement (GlobeNewswire)
Mar-05-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.15%
Mar-01-24 08:09AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.17%
08:00AM	Fate Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-27-24 09:16AM	Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y (Zacks) +7.34%
08:07AM	Q4 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-24 05:10PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:35PM	Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
04:08PM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-19-24 10:00AM	Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-15-24 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.09%
Feb-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-30-24 07:54AM	Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock? (Zacks)
Jan-29-24 02:53PM	Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock (InvestorPlace) +25.44%
Jan-08-24 08:00AM	Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors (GlobeNewswire) +9.28%
Dec-22-23 12:00PM	Fate Therapeutics (FATE) Upgraded to Buy: Here's Why (Zacks)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-13-23 05:00PM	Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.67% +11.19%
Dec-08-23 11:30AM	Fate Therapeutics (FATE) Up 10.3% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-09-23 01:18PM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call Transcript (Insider Monkey) -8.58%
Nov-08-23 06:18PM	Fate Therapeutics Inc (FATE) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:08PM	Fate Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Oct-25-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results (GlobeNewswire) -7.22%
Sep-15-23 06:01AM	Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength? (Zacks) -6.78%
Sep-07-23 11:30AM	Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report? (Zacks)
Aug-31-23 08:00AM	Fate Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-29-23 07:30AM	16 Most Shorted Stocks Right Now (Insider Monkey)
Aug-09-23 12:12PM	FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss (Zacks)
11:04AM	Q2 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:11PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Jul-28-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-22-23 08:35AM	One Fate Therapeutics Insider Raised Stake By 83% In Previous Year (Simply Wall St.)
Jul-01-23 10:33AM	We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-16-23 03:53PM	Why Shares of Fate Therapeutics Soared This Week (Motley Fool)
Jun-14-23 06:42AM	Editas (EDIT) Surges 15.5%: Is This an Indication of Further Gains? (Zacks)
Jun-08-23 11:30AM	Halozyme Therapeutics (HALO) Up 0.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-07-23 11:30AM	Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report? (Zacks)
Jun-04-23 08:27AM	Fate Therapeutics, Inc.'s (NASDAQ:FATE) Low P/S No Reason For Excitement (Simply Wall St.)
Jun-02-23 11:31AM	Fate Therapeutics (FATE) Down 17.8% Since Last Earnings Report: Can It Rebound? (Zacks)
May-31-23 08:00AM	Fate Therapeutics to Present at Upcoming June Investor Conferences (GlobeNewswire)
May-25-23 10:49AM	Cathie Wood is Selling These 12 Stocks in 2023 (Insider Monkey) -5.62%
May-08-23 06:05AM	Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher (Simply Wall St.)
May-04-23 11:59AM	FATE Incurs Narrower-Than-Expected Q1 Loss on Lower Expenses (Zacks)
11:22AM	Q1 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.76%
04:11PM	Fate Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
12:00PM	Fate Therapeutics (FATE) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-27-23 10:03AM	Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-26-23 10:02AM	Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-24-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results (GlobeNewswire)
Apr-12-23 07:20AM	Shareholders in Fate Therapeutics (NASDAQ:FATE) are in the red if they invested a year ago (Simply Wall St.)
Mar-30-23 11:30AM	Why Is Fate Therapeutics (FATE) Down 8.9% Since Last Earnings Report? (Zacks)
Mar-27-23 09:00AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Mar-03-23 04:01PM	Fate Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Mar-02-23 09:18PM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript (Insider Monkey)
05:30AM	Fate Therapeutics Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-01-23 09:59AM	FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Feb-28-23 05:15PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Feb-27-23 09:31AM	Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More (Zacks)
Feb-13-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-06-23 09:55AM	Wall Street Analysts Believe Fate Therapeutics (FATE) Could Rally 172.49%: Here's is How to Trade (Zacks)
Feb-02-23 09:46AM	GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities (GlobeNewswire) +7.22%
Jan-30-23 07:33AM	Calculating The Fair Value Of Fate Therapeutics, Inc. (NASDAQ:FATE) (Simply Wall St.)

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Xu Yuan	Director	Aug 06 '24	Sale	4.23	633	2,678	8,669	Aug 07 04:01 PM
Xu Yuan	Director	Aug 06 '24	Proposed Sale	4.23	633	2,678		Aug 06 10:34 AM
Dulac Edward J III	Chief Financial Officer	Mar 04 '24	Sale	7.77	2,447	19,013	101,479	Mar 05 04:24 PM
Dulac Edward J III	Chief Financial Officer	Jan 29 '24	Sale	5.00	1,849	9,245	103,926	Jan 30 04:01 PM
TAHL CINDY	General Counsel and Secretary	Jan 09 '24	Sale	4.37	10,874	47,519	142,361	Jan 10 04:30 PM
Valamehr Bahram	Chief R&D Officer	Jan 09 '24	Sale	4.38	11,271	49,367	158,069	Jan 10 04:30 PM
Wolchko J Scott	President and CEO	Jan 09 '24	Sale	4.37	14,391	62,889	371,248	Jan 10 04:29 PM
Dulac Edward J III	Chief Financial Officer	Jan 09 '24	Sale	4.37	7,028	30,712	105,775	Jan 10 04:29 PM
Dulac Edward J III	Chief Financial Officer	Jan 02 '24	Sale	3.66	5,182	18,966	112,803	Jan 03 04:03 PM
Redmile Group, LLC	Director	Dec 26 '23	Buy	3.72	44,630	166,024	13,180,388	Dec 28 09:30 PM
Dulac Edward J III	Chief Financial Officer	Dec 18 '23	Sale	3.50	1,585	5,548	117,985	Dec 19 04:01 PM
TAHL CINDY	General Counsel and Secretary	Nov 09 '23	Sale	2.40	24,363	58,471	153,235	Nov 13 04:01 PM

AURA

Aura Biosciences Inc

FATE

Fate Therapeutics Inc

Upgrade your FINVIZ experience